Limited Systemic Absorption of Intraperitoneal Ceftizoxime in a Patient with Serratia Marcescens Peritonitis
Authors:
Open Access
- 1 July 1997
- journal article
- research article
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 17 (4) , 395-397
Abstract
Ceftizoxime is a third-generation, semisynthetic cephalosporin that has activity against many grampositive and gram-negative micro-organisms. In the treatment of continuous ambulatory peritoneal dialysis (CAPD) peritonitis, ceftizoxime is usually reserved for organisms which show in vitro susceptibility once the organism has been cultured (1). The pharmacokinetics of ceftizoxime have been previously studied in CAPD patients without peritonitis (2). However, there are no pharmacokinetic data or efficacy studies of ceftizoxime in patients with peritonitis. We report dialysate and serum levels following the use of intraperitoneal (IP) ceftizoxime for the treatment of peritonitis caused by Serratia marcescens.Keywords
This publication has 3 references indexed in Scilit:
- Reviews and Original ArticlesPeritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis, 1996
- Pharmacokinetic issues in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitisJournal of Antimicrobial Chemotherapy, 1995
- Ceftizoxime elimination kinetics in continuous ambulatory peritoneal dialysisClinical Pharmacology & Therapeutics, 1983